MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction
Authors:
- 1 April 2016
- journal article
- Published by Elsevier in Acta Biomaterialia
- Vol. 35, 260-268
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81227902, 21305156, 21575157)
This publication has 45 references indexed in Scilit:
- Histidine–Iridium(III) Coordination-Based Peptide Luminogenic Cyclization and Cyclo-RGD Peptides for Cancer-Cell TargetingJournal of the American Chemical Society, 2014
- A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signalsNature Materials, 2013
- Targeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin NanoparticlesACS Nano, 2011
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialThe Lancet, 2011
- A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cellsJournal of Controlled Release, 2009
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnnals of Oncology, 2006
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group TrialJournal of Clinical Oncology, 2001